In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

COVID-19 intensifies need for and uptake of digital healthcare
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

The Need to Scale Up Digital Health in the Post-Covid World
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Aptar Pharma talks training solutions and education for self-injection
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

How High Quality Film and Coated Elastomeric Stoppers Can Accelerate and Derisk your ...
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions